Clinical trials: Philadelphia-Positive ALL

Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia

Compassionate Use Ponatinib

• No Longer Available
• Age: 18 years and older
• Expanded access

The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias.

Trial name

NCT01549548

Testing

Ponatinib

Where

United States

Sponsor

OHSU Knight Cancer Institute